Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Strength Training for Skeletal Muscle Adaptation After Stroke

7. juni 2018 oppdatert av: VA Office of Research and Development
Chronically disabled stroke survivors experience accelerated skeletal muscle atrophy and other detrimental changes to muscle and surrounding tissues on the paretic side. This unilateral tissue-level damage contributes to worsening disability and insulin resistance. This VA Merit Award will advance the investigators' understanding of the potential for strength training (ST) to reverse stroke-related muscle abnormalities to improve metabolic health, strength, and function. It will be the first study to thoroughly investigate the effects of ST on muscle atrophy, intramuscular fat, muscle fiber characteristics, capillary density and insulin sensitivity after stroke.

Studieoversikt

Detaljert beskrivelse

This study investigates the hypothesis that a novel, high intensity, high repetition ST program will improve abnormalities in paretic and non-paretic leg muscle volume and composition compared to an attention-matched control regimen of supervised stretching over a 3-month intervention period in those disabled by stroke. The investigators further hypothesize that ST-induced skeletal muscle adaptation will translate into improved insulin sensitivity, strength, and function in this population. The specific objectives are to: 1) Determine the effects ST compared to a control intervention on paretic and non-paretic abnormalities in skeletal muscle volume, intramuscular fat, muscle fiber distribution, muscle capillary density, and muscle inflammation in chronically disabled stroke survivors. 2) Determine the effects ST compared to a control intervention on insulin sensitivity in stroke survivors, and whether structural and cellular skeletal muscle mechanisms contribute to improvements in insulin sensitivity after ST. 3) Determine the effects ST compared to a control intervention on physical function (strength, walking speed and balance) in stroke survivors, and whether structural skeletal muscle mechanisms predict ST-induced functional improvement.

The project design consists of 4 phases over 5 months for stroke participants enrolled in either of the two intervention arms (ST vs. CONTROL). During phase 1 the investigators will screen and consent chronic stroke patients with residual gait deficits. Phase 2 (3 weeks) will consist of baseline testing that includes dual energy X-ray absorptiometry (DEXA) scanning, bilateral CT scanning of the legs, bilateral vastus lateralis muscle biopsies, strength testing, timed walks, balance measurements, oral glucose tolerance testing, and hyperglycemic clamp testing. Following completion of baseline testing, volunteers are to be randomized to ST or the CONTROL group. Phase 3 (Intervention Phase, 3 months) will begin with 2 sessions of acclimatization for those assigned to the ST group. ST will then be progressed to 2 sets of 20 repetitions on each leg on each machine (Keiser Leg Press, Leg Extension, Leg Curl) with gradual increases in resistance over 3 months. Those in the CONTROL group will receive equal exposure to health care personnel in the Baltimore VA Exercise facility, performing a full battery of upper and lower body passive and active stretching exercises at each intervention session. In Phase 4 all baseline testing and laboratory analyses will be repeated.

Developing evidence-based therapies to combat skeletal muscle deterioration is highly relevant for chronically disabled stoke survivors. There is mounting evidence that current models of post-stroke rehabilitation are not optimal for maximizing recovery of muscle mass, strength, and metabolic health. The proposed research will develop new insight into the utility of progressive ST for reversing detrimental changes to gross muscle composition, muscle molecular phenotype, muscle inflammation, and muscle capillarization. Changes to any or all of these muscle parameters should have measurable impact on both whole body insulin sensitivity and function. Collectively, the results from this trial may change the current standard of care for stroke survivors by providing evidenced reasons for augmenting physical therapists' treatments, allowing more intense and diverse therapy sessions for maintenance of skeletal muscle.

Studietype

Intervensjonell

Registrering (Faktiske)

38

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Maryland
      • Baltimore, Maryland, Forente stater, 21201
        • Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

40 år til 85 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Stroke greater than 6 months prior with residual hemiparetic gait in women or men aged 40-85 years
  • Completion of all regular post-stroke physical therapy
  • Adequate language and neurocognitive function to participate in testing and training and to give adequate informed consent

Exclusion Criteria:

  • Alcohol consumption greater than 3 oz. liquor, or 3 x 4 oz glasses of wine, or 3 x 12 oz. beers per day, by self-report
  • clinical history of:

    • unstable angina
    • recent (less than 3 months) myocardial infarction or congestive heart failure (NYHA category II)
    • hemodynamically significant valvular dysfunction
    • peripheral arterial occlusive disease (PAOD) with claudication
    • major orthopedic, chronic pain, or non-stroke neuromuscular disorders restricting exercise
    • pulmonary or renal failure
    • poorly controlled hypertension (greater than 190/110)
    • recent hospitalization for severe disease or surgery
    • severe or global receptive aphasia which confounds reliable testing and training
  • Allergy to lidocaine
  • Known muscle disorder
  • Taking Coumadin or Lovenox (contraindication for muscle biopsies)
  • Dementia
  • Untreated major depression

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm 1
Participants in this group undergo lower-extremity strength training on three pneumatic resistance machines (Keiser Leg Press, Keiser Leg Extension, and Keiser Leg Curl). Training sessions happen 3 times per week (M,W,F) and last approximately 45 minutes to 1 hour. Participants in this group exercise each limb individually to account for the large discrepancies in strength between legs in stroke survivors.
3x per week lower-extremity ST lasting approximately 45 minutes to 1 hour.
Aktiv komparator: Arm 2
Participants in this group receive equal exposure to study staff compared with the experimental ST group (approximately 45 minutes to 1 hour 3 times per week). Exercise sessions for this group involve a full battery of active and passive...upper and lower body...stretching and range of motion exercises performed on raised padded tables.
3x per week upper and lower body stretching mixed with active and passive range of motion exercises

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in 1-repetition Maximum (RM) Muscle Strength (Leg Press, Paretic Side)
Tidsramme: Baseline, 3 months
Baseline, 3 months
Change in 1-RM Muscle Strength (Leg Press, Non-Paretic Side)
Tidsramme: Baseline, 3 months
Baseline, 3 months
Change in 1-RM Muscle Strength (Leg Extension, Paretic Side)
Tidsramme: Baseline, 3 Months
Baseline, 3 Months
Change in 1-RM Muscle Strength (Leg Extension, Non-Paretic Side)
Tidsramme: Baseline, 3 Months
Baseline, 3 Months
Change in Leg Muscle Endurance (Paretic Side)
Tidsramme: Baseline, 3 Months
Tests how training impacts the total number of submaximal repetitions a participant can perform according to standardized cadence (at the same absolute level of resistance, pre and post).
Baseline, 3 Months
Change in Leg Muscle Endurance (Non-Paretic Side)
Tidsramme: Baseline, 3 months
Tests how training impacts the total number of submaximal repetitions a participant can perform according to standardized cadence (at the same absolute level of resistance, pre and post).
Baseline, 3 months
Change in 6-minute Walk Distance
Tidsramme: Baseline, 3 Months
Baseline, 3 Months
Change in 10 Meter Walking Speed (Self-Selected)
Tidsramme: Baseline, 3 months
Baseline, 3 months
Change in 10 Meter Walking Speed (Fastest)
Tidsramme: Baseline, 3 Months
Baseline, 3 Months
Change in Peak Aerobic Capacity (VO2 Peak)
Tidsramme: Baseline, 3 Months
Baseline, 3 Months
Change in Berg Balance Scale
Tidsramme: Baseline, 3 months
This measure is a 14 item scale, with each item scored (0-4) and summed for a maximum score of 56 points. Range is 0-56 and higher values represent a better outcome.
Baseline, 3 months
Change in Paretic Limb Step Time (Self-Selected)
Tidsramme: Baseline, 3 months
This and other measures come from Instrumented Walkway (Gait Rite)
Baseline, 3 months
Change in Paretic Limb Step Time (Fastest)
Tidsramme: Baseline, 3 Months
This and other measures come from Instrumented Walkway (Gait Rite)
Baseline, 3 Months
Change in Non-Paretic Limb Step Time (Self-Selected)
Tidsramme: Baseline, 3 months
This and other measures come from Instrumented Walkway (Gait Rite)
Baseline, 3 months
Change in Non-Paretic Limb Step Time (Fastest)
Tidsramme: Baseline, 3 Months
This and other measures come from Instrumented Walkway (Gait Rite)
Baseline, 3 Months
Change in Paretic Limb Step Length (Self-Selected)
Tidsramme: Baseline, 3 Months
This and other measures come from Instrumented Walkway (Gait Rite)
Baseline, 3 Months
Change in Paretic Limb Step Length (Fastest)
Tidsramme: Baseline, 3 months
This and other measures come from Instrumented Walkway (Gait Rite)
Baseline, 3 months
Change in Non-Paretic Limb Step Length (Self-Selected)
Tidsramme: Baseline, 3 Months
This and other measures come from Instrumented Walkway (Gait Rite)
Baseline, 3 Months
Change in Non-Paretic Limb Step Length (Fastest)
Tidsramme: Baseline, 3 Months
This and other measures come from Instrumented Walkway (Gait Rite)
Baseline, 3 Months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. april 2009

Primær fullføring (Faktiske)

31. august 2013

Studiet fullført (Faktiske)

6. juni 2018

Datoer for studieregistrering

Først innsendt

22. januar 2009

Først innsendt som oppfylte QC-kriteriene

22. januar 2009

Først lagt ut (Anslag)

23. januar 2009

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. juli 2018

Siste oppdatering sendt inn som oppfylte QC-kriteriene

7. juni 2018

Sist bekreftet

1. juni 2018

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

Nei

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Exercise- Strength Training

3
Abonnere